Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | glucagon-like peptide 1 receptor | Starlite/ChEMBL | No references |
Homo sapiens | hepatocyte nuclear factor 4, alpha | Starlite/ChEMBL | No references |
Homo sapiens | perilipin 1 | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Loa Loa (eye worm) | nuclear hormone receptor family member nhr-49 | Get druggable targets OG5_131038 | All targets in OG5_131038 |
Schistosoma mansoni | hepatocyte nuclear factor 4-alpha (hnf-4-alpha) | Get druggable targets OG5_131038 | All targets in OG5_131038 |
Schistosoma japonicum | Hepatocyte nuclear factor 4-beta, putative | Get druggable targets OG5_131038 | All targets in OG5_131038 |
Echinococcus multilocularis | hepatocyte nuclear factor 4 alpha | Get druggable targets OG5_131038 | All targets in OG5_131038 |
Brugia malayi | Nuclear hormone receptor family member nhr-49 | Get druggable targets OG5_131038 | All targets in OG5_131038 |
Echinococcus granulosus | hepatocyte nuclear factor 4 alpha | Get druggable targets OG5_131038 | All targets in OG5_131038 |
Schistosoma japonicum | Transcription factor HNF-4 homolog, putative | Get druggable targets OG5_131038 | All targets in OG5_131038 |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Loa Loa (eye worm) | pigment dispersing factor receptor c | glucagon-like peptide 1 receptor | 463 aa | 388 aa | 25.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Brugia malayi | latrophilin 2 splice variant baaae | 0.0041 | 0.1801 | 0.1801 |
Loa Loa (eye worm) | hypothetical protein | 0.006 | 0.3354 | 0.3354 |
Brugia malayi | Corticotropin releasing factor receptor 2 precursor, putative | 0.006 | 0.3354 | 0.3354 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.006 | 0.3354 | 0.3354 |
Echinococcus granulosus | hepatocyte nuclear factor 4 alpha | 0.0142 | 1 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0041 | 0.1801 | 0.1901 |
Schistosoma mansoni | hepatocyte nuclear factor 4-alpha (hnf-4-alpha) | 0.0135 | 0.9475 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0041 | 0.1801 | 0.1801 |
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.006 | 0.3354 | 0.3354 |
Loa Loa (eye worm) | nuclear hormone receptor family member nhr-49 | 0.0142 | 1 | 1 |
Echinococcus multilocularis | hepatocyte nuclear factor 4 alpha | 0.0142 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (functional) | 7.701 uM | PubChem BioAssay. Counterscreen for inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5): Luminescence-based biochemical high throughput dose response assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-1 (PLIN1). (Class of assay: confirmatory) | ChEMBL. | No reference |
IC50 (functional) | 15.697 uM | PubChem BioAssay. Counterscreen for inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5): Luminescence-based biochemical high throughput dose response assay to identify inhibitors of Hepatocyte nuclear factor 4 (HNF4) dimerization. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 11.2202 uM | PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.